Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Differentiated pharmacotherapy of generalized anxiety disorder

Kostyukova E. G., Ladyzhensky M. Ya.
Federal Medical Research Center for Psychiatry and Narcology by the name of V.P.Serbsky Minzdrava RF

This article discusses the possibility of a differentiated approach to the selection of medications for the treatment of generalized anxiety disorder (GAD), principles and approaches to therapy are formulated that correspond to modern aspirations for personified medicine. In the existing recommendations for GAD therapy, the clinical features of the drugs are not taken into account and the principle of compliance of the spectrum of psychotropic activity of the patient's psychopathological structure chosen for therapy with the drug is not taken into account and is not observed.

Based on the literature data analysis, it is shown that the drugs used to treat GAD differ in the spectrum of their somatotropic and psychotropic effects. These spectra should be taken into account in the initial choice of the drug and correspond to the somato-neurological status of the patient and the clinical features of the course of the disease. In particular, it has been shown that with the prevalence of somatic anxiety in the patient's status, prescribing pregabalin or short courses of benzodiazepine anxiolytics is advisable. Antidepressants are more indicated when psychic anxiety predominates. Such patients can also be prescribed pregabalin.

References: 
  • 1. Diagnostic and statistical manual of mentaldisorders. 4th-Text Revision ed. – Washington, DC: American Psychiatric Association, 2000.
  • 2. Vsemirnaya organizatsiya zdravookhraneniya. Mezhdunarodnaya klassifikatsiya boleznei (10-i peresmotr). – SPb.: Overlaid, 1994. – 202 s.
  • 3. Vel'tishchev D.Yu., Marchenko A.S. Generalizovannoe trevozhnoe rasstroistvo: problemy diagnostiki, prognoza i psikhofarmakoterapii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 1 – C. 29–35.
  • 4. Kessler R.C., Chiu W.T., Demler O. et al. Prevalence, severity and comorbidity of 12-month DSM-IV disorders in NCSR // Arch Gen Psychiatr. – 2005. – Vol. 62. – P. 617–627.
  • 5. Kessler R.C., Keller M.B., Wittchen H.U. The epidemiology of generalized anxiety disorder // Psychiatr Clin North Am. – 2001. – No 24. – P. 19–39.
  • 6. Risa B. Weisberg. Overview of generalized anxiety disorder: epidemiology, presentation, and course // J Clin Psychiatry. – 2009. – Vol. 70, suppl. 2. – P. 4–9.
  • 7. Wittchen H.U., Carter R.M., Pfister H. et al. Disabilities and quality of life in pure and comorbid GAD and major depression in a national survey // Int Clin Psychopharmacol. – 2000. – No. 15. – P. 319–328.
  • 8. Demcheva N.K., Yazdovskaya A.V., Sidoryuk O.V. i dr. Epidemiologicheskie pokazateli i pokazateli deyatel'nosti psikhiatricheskikh sluzhb v Rossiiskoi Federatsii (2005–2013 gg.): statisticheskii spravochnik. – M.: FGBU «FMITsPN im. V.P. Serbskogo» Minzdrava Rossii, 2015. – 572 c.
  • 9. Mosolov S.N., Alfimov P.V. Algoritm biologicheskoi terapii generalizovannogo trevozhnogo rasstroistva // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2015. – № 2. – S. 24–28.
  • 10. Kostyukova E.G. Opisanie klinicheskogo sluchaya. Generalizovannoe trevozhnoe rasstroistvo s komorbidnoi depressiei // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2015. – № 1. – S. 31–36.
  • 11. Brawman-Mintzer O., Ludiard R. B., Emmanuel N. et al. Psychiatric comorbidity in patients with generalized anxiety disorder // Am J Psychiatry. – 1993. – No 150. – P. 1216–1218.
  • 12. Sanderson W.C., Barlow D.H. A description of patients diagnosed with DSM- III-R generalized anxiety disorder // J Nerv Ment Dis. – 1990. – No 178. – P. 588–591.
  • 13. Kessler R.S., Greenberg P.G. The economic burden of anxiety and stress disorders // Neuropsychopharmacology: The Fifth Generation of Progress / Ed. by K.L. Davis, D. Charney, J.T. Coyle, Ch. Nemeroff. – American College of Neuropsy chopharmacology, 2002.
  • 14. Vrown T.A., Barlow D.H. Comorbidity among anxiety disorders: implications for treatment and DSM-IV // J Consult Clin Psychol. – 1992. – No 60. – P. 835–855.
  • 15. Brown T.A., Barlow D.H., Liebowitz M.R. The empirical basis of generalized anxiety disorder // Am J Psychiatry. – 1994. – No 151. – P. 1272–1280.
  • 16. Kessler R.C., McGonagle K.A., Zhao S. et al. Lifetime and 12-montth prevalence of DSM-III-R psychiatric disorders in United States: results from the National Comorbidity Survey // Arch Gen Psychiatry. – 1994. – No 51. – P. 8–19.
  • 17. Angst J. Comorbidity of anxiety, phobia, compulsion and depression // Int J Clin Psychopharmacol. – 1993. – No 8, suppl. 1. – P. 21–25.
  • 18. Mosolov C.N. Trevozhnye i depressivnye rasstroistva: komorbidnost' i terapiya. – M.: Artinfo Pablishing, 2007. – C. 63.
  • 19. Chakhava V.O., Less Yu.E. Kliniko-epidemiologicheskoe issledovanie generalizovannogo trevozhnogo rasstroistva // Sotsial'naya i klinicheskaya psikhiatriya. – 2008. – № 1, t. 18. – C. 38–41.
  • 20. Rouillon F., Chignon J.M. Psychiatric comorbidity of anxiety disorders in the year 2000: Controversies and perspectives / Costa-e-Silva J.A. (ed.) // Proceeding of the meeting held in Paris 9, June 1992. – P. 26–34.
  • 21. Wittchen H.-U., Lieb R., Schuster P. et al. When is onset? investigations into early developmental stages of anxiety and depressive disorders // Rapoport J.L. (ed.) Childhood Onset of “Adult” Psychopathology: Clinical and Research Advances. – Washington, DC: American Psychiatric Press, 1999. – P. 259–302.
  • 22. Neznanov N.G., Martynikhin I.A., Mosolov S.N. Diagnostika i terapiya trevozhnykh rasstroistv v Rossiiskoi Federatsii: rezul'taty oprosa vrachei-psikhiatrov // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2017. – № 2. – S. 2–3. DOI: 10.21265/PSYPH.2017.41.6437
  • 23. Bandelou B. Rekomendatsii Vsemirnoi federatsii obshchestv biologicheskoi psikhiatrii (WFSBP) po farmakoterapii trevogi, obsessivno-kompul'sivnogo i posttravmaticheskogo rasstroistva. Pervyi peresmotr // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2012. – № 1. – S. 22–31.
  • 24. Avrutskii G.Ya., Gurovich I.Ya., Gromova V.V. Farmakoterapiya psikhicheskikh zabolevanii. – M.: Meditsina, 1974. – 471 s.
  • 25. Avrutskii G.Ya., Neduva A.A. Lechenie psikhicheski bol'nykh: rukovodstvo dlya vrachei. – M.: Meditsina, 1981. – 495 s.
  • 26. Mosolov S.N. Osnovy psikhofarmakoterapii. – M.: Vostok, 1996. – 288 s.
  • 27. Cipriani A., Furukawa T.A., Salanti G. et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis // Lancet. – 2009. – Feb. 28. – No 373 (9665). – P. 746–758. – PMID: 19185342.
  • 28. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007. Comparative Effectiveness Review / RTI–UNC Evidence-based Practice Center Research Triangle Park, NC. – AHRQ Publication No. 12-EHC012-EF. – 2011. – No 46.
  • 29. Mosolov S.N. Klinicheskoe primenenie sovremennykh antidepressantov. – SPb.: Meditsinskoe informatsionnoe agentstvo, 1995. – 568 s.
  • 30. Kostyukova E.G., Mosolov S.N. Differentsirovannyi podkhod k primeneniyu antidepressantov // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 3. – C. 2–10.
  • 31. Wensel T.M., Powe K.W., Cates M.E. Pregabalin for the Treatment of Generalized Anxiety Disorder // The Annals of Pharmacotherapy. – 2012. – March. – Vol. 46. – P. 424–429.
  • 32. Klinicheskaya farmakologiya / pod red. V.G. Kukesa. Izd.3-e, pererab. – M., 2006.
  • 33. Ansseau M., Dierick M., Buntinkx F., Cnockaert P., De Smedt J., Van Den Haute M., Vander Mijnsbrugge D. High prevalence of mental disorders in primary care // Journal of Affective Disorders. – 2004. – Vol. 78, No 1. – P. 49–55.
  • 34. Borkovec T.D., Robinson E., Pruzinsky T. DePree J.A. Preliminary exploration of worry: Some characteristics and processes // Behaviour Research and therapy. – 1983. – No 21. – P. 9–16.
  • 35. Hoehn-Saric M.D., McLeod D.R., Funderburk F., Kowalski P. Somatic symptoms and physiologic responses in generalized anxiety disorder and panic disorder. An ambulatory monitor study // Archives of General Psychiatry. – 2004. – No 61. – P. 913–921.
  • 36. Wilhelm F.H., Trabert W., Roth W.T. Physiologic instability in panic disorder and generalized anxiety disorder // Biological Psychiatry. – 2001. – No 49. – P. 596–605.
  • 37. Wittchen H.-U., Hoyer J. Generalized Anxiety Disorder: Nature and Course // Journal of Clinical Psychiatry. – 2001. – Vol. 62, No.11. – P. 15–18.
  • 38. Roy-Byrne P.P., Wagner A. Primary care perspectives on generalized anxiety disorder // Journal of Clinical Psychiatry. – 2004. – Vol. 65, No.13. – P. 20–26.
  • 39. Kartal M. Challenges and Opportunities in Diagnosis and Management of Generalized Anxiety Disorder in Primary Care // Anxiety and Related Disorders / edited by Ágnes Szirmai. – 2011. – P. 71–86.
  • 40. Wittchen H.-U., Kessler R.C., Beesdo K., Krause P., Hö er M., Hoyer J. Generalized anxiety disorder and depression in primary care: prevalence, recognition, and management // J Clin Psychiatry. – 2002. No 63, suppl. 8. – P. 24–34.
  • 41. Ray A., Sheehan D.V. Antidepressants in the treatment of generalized anxiety disorder // Generalized anxiety disorder, Symptomatology, Patogenesis and Management / Ed by Nutt D., Ricrels K., Stein D.J., Martin Dunitz. – 2002. P. 137–152.
  • 42. Sheehan D.V. Overcoming anxiety attacs and phobias: a patient’s guide // Drug Therapy. – 1982. –No 12. – P. 67–72.
  • 43. Sheehan D.V. et al. Some biochemical correlates of panic attacs with agoraphobia and their response to a new treatment // J Clin Psychopharmacol. – 1984. – No 4. – P. 66–75.
  • 44. Chouinard G. et al. Alprazolame in the treatment of generalized anxiety and panic disorders: a double dlind placebo controlled study // Psychopharmacology. – 1982. – No. 77. – P. 229–233.
  • 45. Rikels K., Downing R., Schweizer E., Hassman H. Antidepressants for the treatment og generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone and diazepam // Arch Gen Psychiatry. – 1993. – No 50. – P. 884–895.
  • 46. Nemeroff C.B. The role of GABA in the pathophysiology and treatment of anxiety disorders // Psychopharmacol Bull. – 2003. – Vol. 37, No 4. – P. 133–146.
  • 47. Rynn M.A., Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment // CNS Spectr. – 2004. – Vol. 9, No 10. – P. 716–723.
  • 48. Lydiard R.B., Rickels K., Herman B., Feltner D.E. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder // Int J Neuropsychopharmacol. – 2010. – Vol. 13, No 2. – P. 229–241.
  • 49. Montgomery S.A., Tobias K., Zornberg G.L. et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-we- ek multicenter randomized double-blind placebo-controlled comparison of pregabalin and venlafaxine // J Clin Psychiat. – 2006. – Vol. 67, No 5. – P. 771–782.
  • 50. Pande A.C., Crockatt J.G., Feltner D.E. et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial // Am J Psychiat. – 2003. – Vol. 160, No 3. – P. 533–540.
  • 51. Pohl R.B., Feltner D.E., Fieve R.R., Pande A.C. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind placebo- controlled comparison of BID vs TID dosing // J Clin Psychopharmacol. – 2005. – Vol. 25, No 2. – P. 151–158.
  • 52. Rickels K., Pollack M.H., Feltner D.E. et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam // Arch Gen Psychiatry. – 2005. – Vol. 62, No 9. – P. 1022–1030.
  • 53. Meoni P., Salinas E., Brault Y., Hackett D. Pattern of symptom impro- vement following treatment with venlafaxine XR in patients with ge- neralized anxiety disorder // J Clin Psychiat. – 2001. – Vol. 62, No 11. – P. 888–893.
  • 54. Syunyakov T.S., Syunyakov S.A., Morozov P.V. Obzor effektivnosti pregabalina pri generalizovannom trevozhnom rasstroistve s pozitsii ego spektral'noi kharakteristiki // Psikhiatriya i psikhofarmakoterapiya. – 2013. – T. 15, № 1. – S. 94–101.
  • 55. Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema). – Vyp. IV. – M.: Ekho, 2003. – 928 s.
  • 56. Kasper S., Herman B., Nivoli G. et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial // Int Clin Psychopharmacol. – 2009. – Vol. 24. – P. 87–96.
  • 57. Montgomery S., Chatamra K., Pauer L. et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder // Br J Psychiat. – 2008. – Vol. 193. – P. 389–394.
  • 58. Hamburg M.A., Collins F.S. The path to personalized medicine // NEJM. – 2010. – Vol. 363. – P. 301–304.